Mucinous ovarian carcinomas (MOCs) are a rare subtype of epithelial ovarian cancer accounting for less than 10% of all epithelial ovarian cancers. Improvements in diagnosis have suggested that the incidence has been overestimated and the true incidence is less than 5% [1]. Adjuvant chemotherapy studies have included mucinous tumors and other less common types of epithelial ovarian cancers together with high-grade serous tumors, the most common subtype.

Sixty-five to eighty percent of mucinous ovarian cancers are diagnosed at an early stage and have an excellent prognosis compared to early-stage serous cancers. The standard treatment approach for stage I MOC is surgery and based upon the surgical and pathological staging, further adjuvant treatment may be needed.